PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 54 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $31,282,616 | -31.3% | 10,123,824 | 0.0% | 0.18% | -31.8% |
Q2 2023 | $45,557,208 | -21.1% | 10,123,824 | 0.0% | 0.26% | -15.9% |
Q1 2023 | $57,705,797 | -5.6% | 10,123,824 | 0.0% | 0.31% | -14.4% |
Q4 2022 | $61,147,897 | -8.6% | 10,123,824 | 0.0% | 0.37% | -16.2% |
Q3 2022 | $66,918,000 | +26.6% | 10,123,824 | 0.0% | 0.44% | +46.0% |
Q2 2022 | $52,846,000 | -24.3% | 10,123,824 | 0.0% | 0.30% | -25.2% |
Q1 2022 | $69,854,000 | -44.6% | 10,123,824 | 0.0% | 0.40% | -34.6% |
Q4 2021 | $126,042,000 | -60.2% | 10,123,824 | 0.0% | 0.61% | -55.9% |
Q3 2021 | $316,370,000 | +9.2% | 10,123,824 | 0.0% | 1.39% | +9.1% |
Q2 2021 | $289,845,000 | -33.9% | 10,123,824 | 0.0% | 1.27% | -33.1% |
Q1 2021 | $438,665,000 | -39.4% | 10,123,824 | +0.1% | 1.90% | -30.3% |
Q4 2020 | $723,988,000 | +137.5% | 10,118,636 | 0.0% | 2.73% | +124.0% |
Q3 2020 | $304,875,000 | – | 10,118,636 | – | 1.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Orbimed Advisors | 10,909,256 | $33,709,601 | 0.72% |
Boxer Capital, LLC | 2,495,018 | $7,709,606 | 0.41% |
Sio Capital Management, LLC | 350,000 | $1,081,500 | 0.34% |
Baker Brothers Advisors | 10,123,824 | $31,282,616 | 0.18% |
EcoR1 Capital, LLC | 1,157,452 | $3,576,527 | 0.12% |
GSA CAPITAL PARTNERS LLP | 70,583 | $218 | 0.02% |
Pale Fire Capital SE | 30,781 | $95,113 | 0.01% |
Woodline Partners LP | 200,000 | $618,000 | 0.01% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 143,957 | $444,827 | 0.00% |
EXCHANGE TRADED CONCEPTS, LLC | 32,907 | $101,683 | 0.00% |